ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

FDA, Clinical Investigators Head Or Showdown Over Demand To See Individual Patient Records

April 18, 1980

ACCC Seeks Greater Role In Clinical Research Priorities; Suggests Up To 400 Cancer Program

April 13, 1979

Kimes Heads NCI Organ Systems Committee; Changes Being Implemented

April 1, 1988

Frozen Section Analysis Helps Avoid Second Surgery

September 30, 2005

New Organ Systems Program Coordinating Center RFA Released

April 1, 1983

Marker Research Plans Described; NCAB May Consider Asking For Special Study Section For Those Grants

March 11, 1983